#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2019 - 10

Inflammatory myocardial disease

Czech version

Authors: Jan Krejčí;  Hana Poloczková
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in: Vnitř Lék 2019; 65(10): 636-642
Category:

Overview

Inflammatory diseases of the heart muscle include myocarditis and inflammatory cardiomyopathy, which is myocarditis associated with a heart muscle dysfunction. The causes of myocardial inflammatory disorders may be infectious, most commonly viral, as well as non-infectious. Diagnosing is difficult, the clinical suspicion of this diagnosis can be established based on clinical picture and non-invasive diagnostic methods, the most important of which is cardiac magnetic resonance imaging. The definitive diagnosis is based on histological and immunohistochemical evidence of inflammation directly from heart muscle samples. These can be obtained by endomyocardial biopsy which is also the gold standard of diagnosis. In addition to the demonstration of inflammatory changes, the exami­nation of biopsy specimens allows for specification of their character and the obtained tissue can also be exami­ned for presence of infectious agents in the myocardium. Based on the findings it is then possible to estimate the prognosis, set the timing of further therapeutic steps (especially device-based therapy) and, in some cases, admi­nister specific treatments.

Keywords:

endomyocardial biopsy – immunosuppressive treatment – myocarditis

Sources
  1. Caforio ALP, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648, 2648a-2648d. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht210>.
  2. Kindermann I, Barth C, Mahfoud F et al. Update on myocarditis. J Am Coll Cardiol 2012; 59(9): 779–792. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.09.074>.
  3. Cooper LT. Myocarditis. N Engl J Med 2009; 360(15): 1526–1538. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0800028>.
  4. Trachtenberg BH, Hare JM. Inflammatory Cardiomyopathic Syndromes. Circ Res 2017; 121(7): 803–818. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.117.310221>.
  5. Lund LH, Edwards LB, Dipchand AI et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indication for Transplant. J Heart Lung Transplant 2016; 35(10): 1158–1169. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2016.08.017>.
  6. Heymans S, Eriksson U, Lehtonen J et al. Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 2016; 68(21): 2348–2364. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.09.937>.
  7. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008; 29(17): 2073–2082. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn296>.
  8. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32(21): 2616–2625.Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr165>.
  9. Krejci J, Mlejnek D, Sochorova D et al. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int 2016; 2016: 4087632. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/4087632>.
  10. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93(5): 841–842. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.93.5.841>.
  11. Aretz HAT, Billingham ME, Edwards WD et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1(1): 3–14.
  12. Kühl U, Noutsias M, Seeberg B et al. Immunohistological evidence for chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75(3): 295–300. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.75.3.295>.
  13. Maisch B, Portig I, Ristic A et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report Herz 2000; 25(3): 200–209.
  14. Caforio ALP, Marcolongo R, Basso C et al. Clinical presentation and diagnosis of myocarditis. Heart 2015; 101(16): 1332–1344. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2014–306363>.
  15. Hufnagel G, Pankuweit S, Richter A et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz 2000; 25(3): 279–285.
  16. Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with „idiopathic“ left ventricular dysfunction. Circulation 2005; 111(7): 887–893. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000155616.07901.35>.
  17. Krejci J, Poloczkova H, Hude P et al. Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor et Vasa 2013; 55(4): e333-e340. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2013.02.003>
  18. Kuethe F, Lindner J, Matschke K et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009; 49(11): 1660–1666. Dostupné z DOI: <http://dx.doi.org/10.1086/648074>.
  19. Escher F, Modrow S, Sabi T et al. Parvovirus B19 profiles in patients with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008; 14: CR589-CR597.
  20. Verdonschot J, Hazebroek M, Merken J et al. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail 2016; 18(12): 1430–1441. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.665>.
  21. Bock CT, Düchting A, Utta F et al. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol 2014; 6(4): 183–195. Dostupné z DOI: <http://dx.doi.org/10.4330/wjc.v6.i4.183>.
  22. Wehlou C, Delanghe JR. Detection of antibodies in cardiac autoimmmunity. Clin Chim Acta 2009; 408(1–2): 114–122. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2009.08.002>.
  23. Caforio AL, Mahon NJ, Tona F et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002; 4(4): 411–417. Dostupné z DOI: <http://dx.doi.org/10.1016/s1388–9842(02)00010–7>.
  24. Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol 2009; 29(6): 730–737. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–009–9339-z>.
  25. Krejci J, Hude P, Ozábalová E et al. Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(4): 524–532. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2016.033>.
  26. Caforio ALP, Calabrese F, Angelini A et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28(11): 1326–1333. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehm076>.
  27. Fairweather D, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 2013; 38(1): 7–46. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cpcardiol.2012.07.003>
  28. D’Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85(5): 499–504. Dostupné z DOI: <http://dx.doi.org/10.1136/heart.85.5.499>.
  29. Krejci J, Hude P, Poloczkova H et al. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy. Heart Vessels 2016; 31(3): 416–426. Dostupné z DOI: <http://dx.doi.org/10.1007/s00380–014–0618–0>.
  30. McCarthy RE, Boehmer JP, Hruban RH et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342(10): 690–695. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200003093421003>.
  31. Kandolin R, Lehtonen J, Salmenkivi K et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6(1): 15–22. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969261>.
  32. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18(6): 733–746. Dostupné z DOI: <http://dx.doi.org/10.1007/s10741–012–9358–3>.
  33. Baccouche H, Mahrholdt H, Meinhardt G et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J 2009; 30(23): 2869–2879. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp328>.
  34. Olimunder MA, van Els J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J 2009; 17(2): 481–486. Dostupné z DOI: <http://dx.doi.org/10.1007/bf03086308>.
  35. Bruder O, Wagner A, Lombardi M et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry – multinational results from 57 centers in 15 countries. J Cardiovasc Magn Reson 2013; 15: 9. Dostupné z DOI: <http://dx.doi.org/10.1186/1532–429X-15–9>.
  36. Lurz P, Eitel I, Adam J et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging 2012; 5(5): 513–524. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.11.022>.
  37. Kuchynka P, Palecek T, Nemecek E et al. New therapeutic aspects on inflammatory cardiomyopathy. Curr Pharm Des 2015; 21(4): 459–465. Dostupné z DOI: <http://dx.doi.org/10.2174/138161282104141204142244>.
  38. Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: a JACC White paper. J Am Coll Cardiol 2009; 53(17): 1475–1487. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.02.007>.
  39. Grün S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59(18): 1604–1615. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.01.007>.
  40. Francone M, Chimenti C, Galea A et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging 2014; 7(3): 254–263. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2013.10.011>.
  41. Ferreira VM, Schulz-Menger J, Holmvang G et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72(24): 3158–3176. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.09.072>.
  42. Mahfoud F, Gärtner B, Kindermann M et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32(7): 897–903. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehq493>.
  43. Heidecker B, Kittleson MM, Kasper EK et al. Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation 2011; 123(11): 1174–1184. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.002857>.
  44. Cooper LT, Onuma OK, Sagar S et al. Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy. Heart Fail Clin 2010; 6(1): 75–85. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2009.08.012>.
  45. Corsten MF, Papageorgiou A, Verhesen W et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 2012; 111(4): 415–425. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.112.267443>.
  46. Mason JW, O´Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333(5): 269–275. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199508033330501>.
  47. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30(16): 1995–2002. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp249>.
  48. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, placebo controled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Circulation 2001; 104(1): 39–45. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.104.1.39>.
  49. Lu C, Qin F, Yan Y et al. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown) 2016; 17(8): 631–637. Dostupné z DOI: <http://dx.doi.org/10.2459/JCM.0000000000000134>.
  50. Merken J, Hazebroek M, Van Paassen P et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circ Heart Fail 2018; 11(2): e004228. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004228>.
  51. Kühl U, Lassner D, von Schlippenbach J et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012; 60(14): 1295–1296. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.06.026>.
  52. Schultheiss HP, Piper C, Sowade O et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016; 105(9): 763–773. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392–016–0986–9>.
Labels
Diabetology Endocrinology Internal medicine
Interdisciplinary cooperation for a maximum acceleration of availability of modern therapy for ischemic stroke for all patients in need of endovascular thrombectomy
Innovations in pharmacological treatment of heart failure
New european guidelines for the diagnosis and treatment of hypertension, issued in 2018 – brief comments
Acute and recurrent pericarditis
Prophylaxis for infective endocarditis – an endless story with a colorful past, an uncertain presence and unclear future
Úvodník
Current and future trends in the treatment of dyslipidemias
Genetic testing in patients with hypertrophic cardiomyopathy
Takotsubo syndrome
Odešel profesor Marek, velký internista, endokrinolog, ale především velký člověk
Z odborné literatury
Article was published in

Internal Medicine

Issue 10
2019 Issue 10
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#